To achieve the ambitious goals of the WHO to eliminate hepatitis C virus (HCV) infection as a public health threat by 2030, innovative approaches are needed to improve the uptake for screening and treatment in people who inject drugs (PWID). Important barriers to care are difficult venous access and the two-step approach in current point-of care tests, using an HCV antibody screening test followed by a confirmatory HCV RNA test. In this study we aimed to validate the new GenXpert instrument to diagnose HCV RNA by fingerprick. This prospective study was conducted in a cohort of PWID in 6 alcohol/drug clinic sites and 1 outreach project in Belgium between January 2018 and March 2019. Plasma and capillary whole blood samples were collected by venepuncture and fingerprick, respectively. Sensitivity and specificity of the GenXpert system were compared to the gold standard Artus HCV RNA kit. Of 153 participants enrolled, 147 (96.1%) had results of both the GenXpert system and Artus HCV RNA kit available. HCV RNA was detected in 35/147 (23.8%) by the Artus HCV RNA kit and in 36/147 (24.8%) by the GenXpert. Median quantitative HCV RNA viral load on fingerprick was 28,700 IU/ml (IQR 4,070-65,875) vs. 1,900,000IU/mL (IQR 416,466-2,265,510) on plasma. The GenXpert instrument had a sensitivity of 100% (95% CI 90-100%) and a specificity of 99.1% (95.1-99.9%). The overall diagnostic accuracy was 99.3% (96.3%-99.9%).This study validates the excellent performance of the GenXpert instrument to assess HCV RNA in capillary whole blood by fingerprick in a PWID cohort.This article is protected by copyright. All rights reserved.
January 7, 2021
- ACC 2020The American College of Cardiology decided to cancel ACC.20/WCC due to COVID-19, which was scheduled to take place March 28-30 in Chicago. However, ACC.20/WCC Virtual Meeting continues to release cutting edge science and practice changing updates for cardiovascular professionals on demand and free through June 2020.
- CROI 2020Every year, CROI hosts some of the world's leading experts in HIV research, who come to present exciting new data and drive forward the field of HIV/AIDS research. This year, due to COVID-19, CROI held their meeting virtually.